Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab

Gian Maria Cavallini,1 Graziella Pellegrini,2 Veronica Volante,1 Pietro Ducange,1 Michele De Maria,1 Giulio Torlai,1 Caterina Benatti,1 Matteo Forlini1 1Institute of Ophthalmology, 2Centre for Regenerative Medicine “Stefano Ferrari”, University of Modena e Reggio Emilia, Modena...

Full description

Bibliographic Details
Main Authors: Cavallini GM, Pellegrini G, Volante V, Ducange P, De Maria M, Torlai G, Benatti C, Forlini M
Format: Article
Language:English
Published: Dove Medical Press 2014-08-01
Series:Clinical Ophthalmology
Online Access:http://www.dovepress.com/chemical-injury-treated-with-autologous-limbal-epithelial-stem-cell-tr-peer-reviewed-article-OPTH
id doaj-9b2b493dad8b492d8f6537d9d4349205
record_format Article
spelling doaj-9b2b493dad8b492d8f6537d9d43492052020-11-24T23:24:50ZengDove Medical PressClinical Ophthalmology1177-54832014-08-012014default1671167318128Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumabCavallini GMPellegrini GVolante VDucange PDe Maria MTorlai GBenatti CForlini M Gian Maria Cavallini,1 Graziella Pellegrini,2 Veronica Volante,1 Pietro Ducange,1 Michele De Maria,1 Giulio Torlai,1 Caterina Benatti,1 Matteo Forlini1 1Institute of Ophthalmology, 2Centre for Regenerative Medicine “Stefano Ferrari”, University of Modena e Reggio Emilia, Modena, Italy Background: Limbal stem cell (LSC) deficiency leads to corneal opacity due to a conjunctivalization of the corneal surface. LSC transplantation, which can be followed by corneal keratoplasty, is an effective procedure to restore corneal transparency; however, a common cause of failure of this procedure is neovascularization (NV).Methods: A 59-year-old man with a 21-year history of a corneal chemical burn caused by phosphoric acid in his left eye was examined. He presented with unilateral total LSC deficiency with severe conjunctivalization and a corrected distance visual acuity that was limited to hand motion.Results: We reported the short-term in vivo efficacy of subconjunctival bevacizumab for progressive corneal NV in a patient with LSC deficiency that underwent LSC transplantation. Four months after autologous LSC transplantation and 1 month after the second subconjunctival bevacizumab injection, the patient’s corrected distance visual acuity was 1/10.Conclusion: Subconjunctival injection of bevacizumab can reduce the corneal NV, reducing conjunctival inflammation and supporting restoration of a stable ocular surface that is able to counteract graft failure, with no toxicity for the transplanted LSC. Keywords: stem cells, bevacizumab, limbal stem cell deficiency, transplantationhttp://www.dovepress.com/chemical-injury-treated-with-autologous-limbal-epithelial-stem-cell-tr-peer-reviewed-article-OPTH
collection DOAJ
language English
format Article
sources DOAJ
author Cavallini GM
Pellegrini G
Volante V
Ducange P
De Maria M
Torlai G
Benatti C
Forlini M
spellingShingle Cavallini GM
Pellegrini G
Volante V
Ducange P
De Maria M
Torlai G
Benatti C
Forlini M
Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab
Clinical Ophthalmology
author_facet Cavallini GM
Pellegrini G
Volante V
Ducange P
De Maria M
Torlai G
Benatti C
Forlini M
author_sort Cavallini GM
title Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab
title_short Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab
title_full Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab
title_fullStr Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab
title_full_unstemmed Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab
title_sort chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab
publisher Dove Medical Press
series Clinical Ophthalmology
issn 1177-5483
publishDate 2014-08-01
description Gian Maria Cavallini,1 Graziella Pellegrini,2 Veronica Volante,1 Pietro Ducange,1 Michele De Maria,1 Giulio Torlai,1 Caterina Benatti,1 Matteo Forlini1 1Institute of Ophthalmology, 2Centre for Regenerative Medicine “Stefano Ferrari”, University of Modena e Reggio Emilia, Modena, Italy Background: Limbal stem cell (LSC) deficiency leads to corneal opacity due to a conjunctivalization of the corneal surface. LSC transplantation, which can be followed by corneal keratoplasty, is an effective procedure to restore corneal transparency; however, a common cause of failure of this procedure is neovascularization (NV).Methods: A 59-year-old man with a 21-year history of a corneal chemical burn caused by phosphoric acid in his left eye was examined. He presented with unilateral total LSC deficiency with severe conjunctivalization and a corrected distance visual acuity that was limited to hand motion.Results: We reported the short-term in vivo efficacy of subconjunctival bevacizumab for progressive corneal NV in a patient with LSC deficiency that underwent LSC transplantation. Four months after autologous LSC transplantation and 1 month after the second subconjunctival bevacizumab injection, the patient’s corrected distance visual acuity was 1/10.Conclusion: Subconjunctival injection of bevacizumab can reduce the corneal NV, reducing conjunctival inflammation and supporting restoration of a stable ocular surface that is able to counteract graft failure, with no toxicity for the transplanted LSC. Keywords: stem cells, bevacizumab, limbal stem cell deficiency, transplantation
url http://www.dovepress.com/chemical-injury-treated-with-autologous-limbal-epithelial-stem-cell-tr-peer-reviewed-article-OPTH
work_keys_str_mv AT cavallinigm chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab
AT pellegrinig chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab
AT volantev chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab
AT ducangep chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab
AT demariam chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab
AT torlaig chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab
AT benattic chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab
AT forlinim chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab
_version_ 1725558483984580608